Standard Chemical & Pharmaceutical Co., Ltd. (TPE:1720)
Taiwan · Delayed Price · Currency is TWD 60.40
-0.70 (-1.15%)
Feb 2, 2026, 1:35 PM CST
TPE:1720 Revenue
Standard Chemical & Pharmaceutical had revenue of 1.77B TWD in the quarter ending September 30, 2025, with 1.56% growth. This brings the company's revenue in the last twelve months to 6.91B, up 3.02% year-over-year. In the year 2024, Standard Chemical & Pharmaceutical had annual revenue of 6.79B with 8.81% growth.
Revenue (ttm)
6.91B
Revenue Growth
+3.02%
P/S Ratio
1.58
Revenue / Employee
n/a
Employees
n/a
Market Cap
10.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.79B | 549.46M | 8.81% |
| Dec 31, 2023 | 6.24B | 388.40M | 6.64% |
| Dec 31, 2022 | 5.85B | 1.25B | 27.09% |
| Dec 31, 2021 | 4.60B | 298.68M | 6.94% |
| Dec 31, 2020 | 4.31B | 368.27M | 9.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grape King Bio | 10.40B |
| YungShin Global Holding | 8.37B |
| TTY Biopharm Company | 6.50B |
| Synmosa Biopharma | 6.11B |
| Formosa Laboratories | 4.90B |
| ScinoPharm Taiwan | 3.19B |
| Handa Pharmaceuticals | 1.62B |
| SCI Pharmtech | 1.39B |